Abstract
Refractory angina pectoris constitutes a manifestation of severe ischemic heart disease that cannot be treated adequately either with conventional medication or with interventional techniques including percutaneous coronary angioplasty (PTCA). As a result, new therapeutic strategies, aiming on angiogenesis, were evolved in order to improve functional class and health related quality of life (HRQOL) indices. Among them, gene therapy constitutes a very promising alternative treatment for these patients. In this review, we will describe i) the definition of refractory angina ii) pathophysiology of angiogenesis, iii) routine as well as novel imaging techniques of neovascularization and iv) current treatment options for refractory angina. Secondly we will review the main angiogenic clinical trials, which will also be commented regarding their effectiveness to reduce the recurrency of angina symptoms and improve health-related quality-of-life, as well as the functional class of patients with chronic ischemic disease.
Keywords: Refractory angina, angiogenesis, vasa vasorum, growth factors, ischemic heart disease, percutaneous coronary angioplasty (PTCA), neovascularization, gene therapy, clinical trials, medication
Current Pharmaceutical Design
Title:Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Volume: 19 Issue: 9
Author(s): Manolis Vavuranakis, Maria Kariori, Konstantinos Kalogeras, DimitriosVrachatis, Carmen Moldovan, Dimitris Tousoulis and Christodoulos Stefanadis
Affiliation:
Keywords: Refractory angina, angiogenesis, vasa vasorum, growth factors, ischemic heart disease, percutaneous coronary angioplasty (PTCA), neovascularization, gene therapy, clinical trials, medication
Abstract: Refractory angina pectoris constitutes a manifestation of severe ischemic heart disease that cannot be treated adequately either with conventional medication or with interventional techniques including percutaneous coronary angioplasty (PTCA). As a result, new therapeutic strategies, aiming on angiogenesis, were evolved in order to improve functional class and health related quality of life (HRQOL) indices. Among them, gene therapy constitutes a very promising alternative treatment for these patients. In this review, we will describe i) the definition of refractory angina ii) pathophysiology of angiogenesis, iii) routine as well as novel imaging techniques of neovascularization and iv) current treatment options for refractory angina. Secondly we will review the main angiogenic clinical trials, which will also be commented regarding their effectiveness to reduce the recurrency of angina symptoms and improve health-related quality-of-life, as well as the functional class of patients with chronic ischemic disease.
Export Options
About this article
Cite this article as:
Vavuranakis Manolis, Kariori Maria, Kalogeras Konstantinos, DimitriosVrachatis , Moldovan Carmen, Tousoulis Dimitris and Stefanadis Christodoulos, Refractory Angina Pectoris: Lessons from the Past and Current Perspectives, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090013
DOI https://dx.doi.org/10.2174/1381612811319090013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Ca2+-Sensitive K+ Currents in Controlling Ventricular Repolarization: Possible Implications for Future Antiarrhytmic Drug Therapy
Current Medicinal Chemistry Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids
Medicinal Chemistry Intervention for Cardiac Repair: A Clinical Perspective
Current Stem Cell Research & Therapy Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry The Coronary Collateral Circulation in Man
Current Cardiology Reviews Effects of Imidazolic Agonism on Blood Pressure, Sympathetic Activity, Left Ventricular Hypertrophy and Insulin Resistance
Current Hypertension Reviews Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Patent Selections
Recent Patents on Cardiovascular Drug Discovery Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Patent Selections:
Current Regenerative Medicine (Discontinued) Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery Effects of Aerobic Exercise and Training on Coagulation, Platelet Aggregation, and Plasma Lipids
Vascular Disease Prevention (Discontinued)